识别银屑病生物制剂治疗有效性的 demographic、社会和临床预测因素:一项多中心纵向队列研究
该多中心观察性前瞻性药物警戒研究(BADBIR)纳入初次使用生物制剂的银屑病患者,6个月随访3079例、12个月随访3110例,评估31个候选预测因素与PASI 90应答的关联。女性、失业、因病失业、吸烟、高体重、掌跖银屑病及仅小斑块与6个月PASI 90几率降低相关,白人种族和高基线PASI与几率升高相关。银屑病表型和潜在可改变因素与生物制剂不良结局相关,但效应量提示这些因素单独不足以指导治疗选择。
要点
- 女性、失业、因病失业、吸烟、高体重、掌跖银屑病及仅小斑块与6个月PASI 90几率降低相关。
- 白人种族和高基线PASI与6个月PASI 90几率升高相关。
- 银屑病表型和潜在可改变因素与生物制剂不良结局相关,但效应量提示这些因素单独不足以指导治疗选择。
核心结论
- 银屑病表型和潜在可改变因素与生物制剂不良结局相关,强调需要生活方式管理,但效应量提示这些因素单独不足以指导治疗选择。
研究设计与样本
- 多中心、观察性、前瞻性药物警戒研究(BADBIR),纳入初次使用生物制剂的银屑病患者,6个月有结局数据者3079例,12个月有结局数据者3110例,采用单变量和多变量回归分析评估31个候选预测因素与结局的关联,并用统计交互作用探索潜在的治疗反应分层因素。
主要发现
- 6个月达到PASI 90几率降低的因素(以OR和95%CI表示):女性0.78(0.66-0.93);失业0.67(0.45-0.99);因病失业0.62(0.48-0.82);曾吸烟0.81(0.66-0.99)和当前吸烟0.79(0.63-0.99);高体重0.99(0.99-0.99);掌跖银屑病0.75(0.61-0.91);与大小斑块均有相比仅小斑块0.78(0.62-0.96)。
- 6个月达到PASI 90几率升高的因素:白人种族OR 1.48(1.12-1.97);较高基线PASI OR 1.04(1.03-1.04)。
- 上述发现在12个月时基本一致,几乎没有证据表明存在差异治疗反应的预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clinical factors that could be used to predict effectiveness and stratify response to biologic therapies in psoriasis. METHODS: Using a multicentre, observational, prospective pharmacovigilance study (BADBIR), we identified biologic-naive patients starting biologics with outcome data at 6 (n = 3079) and 12 (n = 3110) months. Associations between 31 putative predictors and outcomes were investigated in univariate and multivariable regression analyses. Potential stratifiers of treatment response were investigated with statistical interactions. RESULTS: Eight factors associated with reduced odds of achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) at 6 months were identified (described as odds ratio and 95% confidence interval): demographic (female sex, 0·78, 0·66-0·93); social (unemployment, 0·67, 0·45-0·99); unemployment due to ill health (0·62, 0·48-0·82); ex- and current smoking (0·81, 0·66-0·99 and 0·79, 0·63-0·99, respectively); clinical factors (high weight, 0·99, 0·99-0·99); psoriasis of the palms and/or soles (0·75, 0·61-0·91); and presence of small plaques only compared with small and large plaques (0·78, 0·62-0·96). White ethnicity (1·48, 1·12-1·97) and higher baseline PASI (1·04, 1·03-1·04) were associated with increased odds of achieving PASI 90. The findings were largely consistent at 12 months. There was little evidence for predictors of differential treatment response. CONCLUSIONS: Psoriasis phenotype and potentially modifiable factors are associated with poor outcomes with biologics, underscoring the need for lifestyle management. Effect sizes suggest that these factors alone cannot inform treatment selection.
引用
- Warren RB, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2018. PMID: 30155885. doi:10.1111/bjd.16776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。